Specify a stock or a cryptocurrency in the search bar to get a summary
Acurx Pharmaceuticals LLC
ACXPAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Address: 259 Liberty Avenue, Staten Island, NY, United States, 10305
Analytics
WallStreet Target Price
11.26 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACXP
Dividend Analytics ACXP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACXP
Stock Valuation ACXP
Financials ACXP
Results | 2019 | Dynamics |